Drostanolone propionate

The principal clinical indication of drostanolone propionate in the United States as well as international markets was the treatment of advanced inoperable breast cancer in women. as an antiestrogenic drug for the treatment of breast cancer. By the time of its release, there were not many alternatives for patients with breast cancer and drostanolone propionate was a revolution for these patients. As it has lower androgenic rate compared to testosterone, the risk of virilization is much lighter. Due to this fact, women, who usually do not respond well to any AAS, were having much greater chance to survive cancer. Drostanolone propionate can also be used for breast tumors that do not respond well to other treatments or also as palliative care for advanced incurable tumors. The effects of the product depend of course on the dose and period of administration. The risk of virilization becomes greater with high doses and continuous administration period. ==Non-medical uses==

Drostanolone propionate is or has been used for physique- and performance-enhancing purposes by competitive athletes, bodybuilders, and powerlifters. ==Side effects==

Drostanolone propionate produces considerably less virilization in women compared to equal doses of testosterone propionate. mild virilization including oily skin, acne, voice deepening, hirsutism, and clitoral enlargement could still occur, and marked virilization could manifest with long-term therapy. ==Pharmacology==

Pharmacodynamics Drostanolone propionate is a prodrug of drostanolone. Pharmacokinetics Drostanolone propionate is not active via the oral route and must be administered via intramuscular injection. The elimination half-life of the drug via this route is approximately 2 days. It has a much longer elimination half-life via intramuscular injection than drostanolone. Drostanolone propionate is metabolized into drostanolone, which is the active form. ==Chemistry==

Drostanolone propionate, or drostanolone 17β-propionate, is a synthetic androstane steroid and a derivative of DHT. It is the C17β propionate (propanoate) ester of drostanolone, which itself is 2α-methyl-4,5α-dihydrotestosterone (2α-methyl-DHT) or 2α-methyl-5α-androstan-17β-ol-3-one. ==History==

Drostanolone and drostanolone propionate were first described in 1959. The related AAS oxymetholone and methasterone (methyldrostanolone) were first described in the same paper as well. ==Society and culture==

Generic names Drostanolone propionate is the generic name of the drug and its , while dromostanolone propionate is the and ; there is no for this form. The generic name of the unesterified form of the drug is drostanolone or dromostanolone and the former is its , , and while there is no . == References ==